Keyword Search
 
2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
12/01/14Medgenics Announces Completion of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares of Common Stock
PHILADELPHIA, Dec. 1, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and the patient's own tissue for the treatment of rare and orphan diseases, today announced the completion of an underwritten public offering of 5,893,750 shares of its common stock, including 768,750 shares sold pursuant to the full exercise of an option previo... 
Printer Friendly Version
11/25/14Medgenics to Present at 26th Annual Piper Jaffray Healthcare Conference
PHILADELPHIA, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Michael Cola, President and CEO, will participate in a fireside chat discussion at the 26th Annual Piper Jaffray Healthcare Conference in New York. The event will take ... 
Printer Friendly Version
11/25/14Medgenics Prices Public Offering of Common Stock
PHILADELPHIA, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN) today announced the pricing of 5,125,000 shares of its common stock in a previously announced underwritten public offering at a price to the public of $4.10 per share. In connection with the offering, Medgenics has also granted the underwriters a 30-day option to purchase up to an additional 768,750 shares of its common stock. Gross proceeds to Medgenics from the sale of shares are expected to be approximately $21.0 ... 
Printer Friendly Version
11/24/14Medgenics Announces Public Offering of Common Stock
PHILADELPHIA, Nov. 24, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. As part of this proposed offering, Medgenics intends to grant the underwriters a 30-day option to purchase up to an additional ... 
Printer Friendly Version
11/12/14Medgenics Announces Rare & Orphan Disease Research Collaboration With The Children's Hospital of Philadelphia
Collaboration will bring together the premier pediatric genomics research organization, Center for Applied Genomics (CAG), with ex vivo gene therapy innovator, Medgenics, to discover and accelerate the development of new therapies for rare and orphan diseases. PHILADELPHIA, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN) today announced a major research collaboration with The Children's Hospital of Philadelphia (CHOP) focused on pediatric rare and orphan genetic diseases.... 
Printer Friendly Version
10/15/14Medgenics Reports Positive Initial Clinical Data and Third Quarter Financial Results
Clinical proof of concept demonstrated with platform technology based on initial MDGN-201 results Two commercial opportunities for MDGN-201 in orphan conditions identified Pre-clinical proof of concept demonstrated with platform technology in peptides, expanding potential orphan opportunities WAYNE, Pa. and MISGAV, Israel, Oct. 15, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN) (the Company), the developer of a proprietary platform for the sustained production and delivery o... 
Printer Friendly Version
10/08/14Medgenics to Host Conference Call to Announce Third Quarter 2014 Results and Provide Initial Clinical Data on MDGN-201 on October 15, 2014
WAYNE, Pa. and MISGAV, Israel, Oct. 8, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN) will host a conference call and live audio webcast on Wednesday, October 15, 2014 at 9 a.m. EDT to discuss third quarter 2014 financial and operational results and to provide initial clinical data from the ongoing MDGN-201 clinical trial, "Safety and Efficacy of Sustained Erythropoietin Therapy of Anemia in Chronic Kidney Disease Patients and End-Stage Renal Disease (ESRD) Dialysis Patients using TARGTEPO... 
Printer Friendly Version
10/07/14Medgenics to Present Initial Clinical Data From MDGN-201 Study at European Society of Gene and Cell Therapy Congress
WAYNE, Pa. and MISGAV, Israel, Oct. 7, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that initial data from its ongoing Phase 1/2 clinical trial of MDGN-201 (TARGTEPOTM), formerly known as EPODURETM, will be presented at the 22nd Annual Congress of the Europe... 
Printer Friendly Version
09/24/14Medgenics to Announce Third Quarter 2014 Results and Provide Initial Clinical Data on MDGN-201 (EPODURE(TM)) Trial on October 15, 2014
WAYNE, Pa. and MISGAV, Israel, Sept. 24, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN) will host a conference call and live audio webcast on Wednesday, October 15, 2014 at 9 a.m. EDT to discuss third quarter 2014 financial and operational results and to provide initial clinical data from the ongoing MDGN-201 trial, "Safety and Efficacy of Sustained Erythropoietin Therapy of Anemia in Chronic Kidney Disease Patients and End-Stage Renal Disease (ESRD) Dialysis Patients Using EPODURE BioPump... 
Printer Friendly Version
09/10/14Medgenics Announces the Appointment of Scott Applebaum as Chief Legal Officer
WAYNE, Pa. and MISGAV, Israel, Sept. 10, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced the appointment of Scott Applebaum as Chief Legal Officer. "We are very excited to have Scott join our management team. He has a demonstrated ability to lead teams... 
Printer Friendly Version
07/16/14Medgenics Reports Second Quarter Financial Results
WAYNE, Pa. and MISGAV, Israel, July 16, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN) (the Company), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today reported financial results for the three and six months ended June 30, 2014 and the filing with the U.S. Securities and Exchange Commission (SEC) of the Company's Q... 
Printer Friendly Version
06/18/14Medgenics Announces Global Head, Research and Development, Garry Neil, M.D. Receives FDA Commissioner's Special Citation Award
WAYNE, Pa. and MISGAV, Israel, June 18, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Garry Neil, M.D., Global Head, Research and Development, has been awarded the Food and Drug Administration's (FDA) Commissioner's Special Citation. The Citation wa... 
Printer Friendly Version
06/16/14Medgenics to Present at Two Upcoming Healthcare Investor Conferences
WAYNE, Pa. and MISGAV, Israel, June 16, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that members of the senior management team will be participating in the following upcoming healthcare investor conferences. Piper Jaffray GenomeRx Symposium on ... 
Printer Friendly Version
06/05/14Medgenics Announces First Patient Implanted in Phase 1/2 Clinical Trial of MDGN-201 (EPODURE)
Trial to Validate a Second Generation Viral Vector for Potential Use in Future Clinical Studies in Rare and Orphan Diseases WAYNE, Pa. and MISGAV, Israel, June 5, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that the first patient has been enrolled in ... 
Printer Friendly Version
05/08/14Medgenics Reports First Quarter Financial Results
WAYNE, Pa. and MISGAV, Israel, May 8, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today reported financial results for the three months ended March 31, 2014 and the filing with the U.S. Securities and Exchange Commission (SEC) of the Company's Quarterly Report on Form... 
Printer Friendly Version
04/15/14Medgenics Awarded $2.2 Million Grant From the Israeli Office of the Chief Scientist
WAYNE, Pa. and MISGAV, Israel, April 15, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT:MDGN) (LSE:MEDU) (LSE:MEDG), the developer of BioPump(TM) a novel technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that its wholly owned subsidiary, Medgenics Medical Israel Ltd. (MMI), was awarded a government grant of up to NIS 7.7 million (approximately ... 
Printer Friendly Version
04/09/14Medgenics Announces Results of 2014 Annual Meeting of Stockholders
WAYNE, Pa. and MISGAV, Israel, April 9, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN) (AIM:MEDU) (AIM:MEDG), the developer of Biopump(TM) a novel technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that all resolutions proposed at the Company's Annual Meeting of Stockholders held yesterday were duly passed. Dr. Sol J. Barer, Dr. Eugene A. ... 
Printer Friendly Version
03/05/14Medgenics, Inc. to Present at the 26th Annual ROTH Capital Growth Conference
WAYNE, Pa. and MISGAV, Israel, March 5, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN) (AIM:MEDU) (AIM:MEDG), the developer of BioPump™, a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Michael Cola, President and CEO, will present a corporate overview at the 26th Annual ROTH Capital Growth Conference in Laguna Niguel o... 
Printer Friendly Version
02/20/14Medgenics Reports 2013 Financial Results
WAYNE, Pa. and MISGAV, Israel, Feb. 20, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE MKT: MDGN) (LSE:MEDU) (LSE:MEDG), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced financial results for the fiscal year ended December 31, 2013 and the filing with the U.S. Securities and Exchange Commission ("SEC") of the Comp... 
Printer Friendly Version
01/07/14Medgenics Issues Stock Options and Restricted Shares to Non-Executive Directors
WAYNE, Pa. & MISGAV, Israel--(BUSINESS WIRE)--Jan. 7, 2014-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the Company), the developer of Biopump(TM) a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that on January 2, 2014, the Company granted options to subscribe for 15,000 shares of the Company’s common stock, par value US$0.0001 (“Common Shares”) (“Options”) ... 
Printer Friendly Version